drugset / Trial / NCT05222828

Effects of Mepivacaine on the Neurological Sequelae of Cerebral Infarction

NCT05222828

Phase 2 Unknown 38 enrolled Assistance Publique - Hôpitaux de Paris
NaSingle-groupOpen-labelTreatment

Summary

A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI. The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, the investigator team will observe a favorable response to subcutaneous mepivacaine injection.

Timeline

Start
2022-06-22
Primary completion
2024-06-22
Completion
2024-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepivacaine Other / unclassified 60 mg Subcutaneous

Indications